{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T03:25:57Z","timestamp":1769311557094,"version":"3.49.0"},"reference-count":31,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["2054\/18"],"award-info":[{"award-number":["2054\/18"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Lacosamide is increasingly being prescribed to pregnant women, although its effects on the developing fetus have not been fully clarified yet. Previously, we have shown that several antiseizure medications, particularly valproate, can affect the expression of carriers of essential compounds in placental cells. Here, our aim was to assess the effect of short ex vivo exposure of human placentas to lacosamide on the expression of carriers of essential nutrients required by the human fetus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Placentas were obtained from cesarean deliveries of women with no known epilepsy. Cotyledons were cannulated and perfused over 180\u2009min in the presence of lacosamide at 2.5\u00a0\u03bcg\/ml (10\u00a0\u03bcmol\u00b7L<jats:sup>\u22121<\/jats:sup>, <jats:italic>n<\/jats:italic>\u00a0=\u20097) or 10\u00a0\u03bcg\/ml (40\u2009\u03bcmol\u00b7L<jats:sup>\u22121<\/jats:sup>, <jats:italic>n<\/jats:italic>\u00a0=\u20096), representing low and high therapeutic concentrations, respectively, in the maternal perfusate. Valproate (83\u2009\u03bcg\/ml, 500\u2009\u03bcmol\u00b7L<jats:sup>\u22121<\/jats:sup>, <jats:italic>n<\/jats:italic>\u00a0=\u20096) and the perfusion solution (<jats:italic>n<\/jats:italic>\u00a0=\u20096) were used as the respective positive and negative controls. A customized gene panel array was used to analyze the expression of carrier genes in the perfused cotyledons.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Following a 3\u2010h perfusion, the mRNA expression of <jats:italic>SLC19A1<\/jats:italic> (encoding the reduced folate carrier 1) was downregulated in placentas treated with 10\u00a0\u03bcg\/ml lacosamide (50%) as compared with the vehicle (<jats:italic>p<\/jats:italic>\u00a0&lt;\u2009.05). Across all groups, a significant difference was observed in the expression of <jats:italic>SLC19A3<\/jats:italic> (thiamine transporter 2; 52%, 20%, and 9% decrease by 10\u00a0\u03bcg\/ml lacosamide, 83\u2009\u03bcg\/ml valproate, and 2.5\u00a0\u03bcg\/ml lacosamide, respectively; <jats:italic>p<\/jats:italic>\u00a0&lt;\u2009.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Significance<\/jats:title><jats:p>Lacosamide at high therapeutic concentrations exerted pharmacological effects on the human placenta. Our findings, if manifested in vivo, suggest that lacosamide could potentially affect folate supply to the fetus and support therapeutic monitoring and careful adjustment of lacosamide plasma concentrations during pregnancy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/epi.17395","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T11:45:09Z","timestamp":1660909509000},"page":"2949-2957","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Lacosamide effects on placental carriers of essential compounds in comparison with valproate: Studies in perfused human placentas"],"prefix":"10.1111","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8745-7120","authenticated-orcid":false,"given":"Erez","family":"Berman","sequence":"first","affiliation":[{"name":"Institute for Drug Research, School of Pharmacy Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elkana","family":"Kohn","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology &amp; Toxicology Unit Assaf Harofeh (Shamir) Medical Center  Beer Yakov Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matitiahu","family":"Berkovitch","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology &amp; Toxicology Unit Assaf Harofeh (Shamir) Medical Center  Beer Yakov Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5443-5670","authenticated-orcid":false,"given":"Michal","family":"Kovo","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Meir Medical Center  Kfar Saba Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1275-6094","authenticated-orcid":false,"given":"Sara","family":"Eyal","sequence":"additional","affiliation":[{"name":"Institute for Drug Research, School of Pharmacy Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,9,3]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2146\/news080095"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16953"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.3880"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15020192"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M101287200"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2015.04.011"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12269"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13037"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13392"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14078"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106664"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14721"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16905"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2019.1105"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-017-2234-8"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(72)90909-X"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/pd.2026"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1385"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64813-4"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2016.04.017"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20040414"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)07104-5"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70323-X"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2015.04.008"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-01914-9"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1139\/bcb-2017-0082"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.5487"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2021.1273"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108253"},{"key":"e_1_2_10_31_1","unstructured":"US Food and Drug Administration.Vimpat (lacosamide). Updated2021Oct 14 [cited 2022 May 14]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/022253s049 022254s039 022255s031lbl.pdf"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01122.x"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.17395","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/epi.17395","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.17395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T07:51:27Z","timestamp":1692604287000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.17395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,3]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/epi.17395"],"URL":"https:\/\/doi.org\/10.1111\/epi.17395","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,3]]},"assertion":[{"value":"2022-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}